[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07284576":3,"trial-entities:NCT07284576":106,"trial-summary:NCT07284576":111},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":23,"study_type":29,"primary_purpose":30,"phases":31,"enrollment_info":33,"interventions":36,"primary_outcomes":47,"secondary_outcomes":70,"sex":71,"minimum_age":72,"maximum_age":73,"healthy_volunteers":15,"eligibility_criteria":74,"std_ages":89,"locations":92,"central_contacts":102,"overall_officials":103,"references":104,"see_also_links":105},"NCT07284576","NII-0007-cardiac","Ultralow Dose PET Imaging of 18F-flurpiridaz","Evaluation of 0.25mCi PET Imaging for Detecting Cardiac Perfusion","ENROLLING_BY_INVITATION","2030-06-30","2026-04","2026-04-13","2025-12-16","Akiva Mintz","OTHER",true,"The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET) imaging technique for known or suspected coronary artery disease (for detecting myocardial ischemia or infarction) detection and monitoring. The main question it aims to answer is:\n\nCan the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-flurpiridaz and be imaged on a new type of high sensitivity PET scanner for up to 3 hours","This research study aims to evaluate an investigational ultralow dose PET imaging technique for known or suspected coronary artery disease (for detecting myocardial ischemia or infarction) detection and monitoring. \"Investigational\" means that the procedure or drug being studied is not yet approved by the U.S. Food and Drug Administration (FDA) for the specific use being tested in this research. The PET imaging technique used in this study is considered investigational because it is being tested at an ultralow radiation dose that has not yet been approved for clinical use. The radiotracer, 18F-flurpiridaz, is FDA-approved for detecting prostate cancer at standard doses.\n\n18F-flurpiridaz is often found to be taken up at higher levels in Known or suspected coronary artery disease (for detecting myocardial ischemia or infarction). In this study, investigators will use a very small amount of this tracer (less than 1\u002F20th of the standard dose) along with advanced PET imaging technology to see if it is possible to create clear images while using much less radiation. This study aims to develop a safer imaging technique that could potentially be used more frequently for screening and monitoring Known or suspected coronary artery disease (for detecting myocardial ischemia or infarction).\n\nInvestigators will enroll individuals with and without Known or suspected coronary artery disease (for detecting myocardial ischemia or infarction) to evaluate how ultralow dose PET imaging detects 18F-flurpiridaz uptake in different type of tissue.\n\nApproximately 200 people will be enrolled in this study at the Nuclear Imaging Institute.",[19,20,21,22],"Healthy Volunteer","Coronary Arterial Disease","Myocardial Ischemia","Myocardial Infarction",[24,25,26,27,28],"PET","PET\u002FCT","low dose","nuclear imaging","cardiac","INTERVENTIONAL","DIAGNOSTIC",[32],"PHASE2",{"count":34,"type":35},200,"ESTIMATED",[37],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":43},"DRUG","18F-flurpiridaz","Participants will be injected with 18F-flurpiridaz and imaged for up to 3 hours on a PET scanner",[42],"ultralow dose 18F-flurpiridaz imaging group",[44,45,46],"CT scan","PET scan","blood collection",[48,52,55,58,61,64,67],{"measure":49,"description":50,"timeFrame":51},"Signal-to-Noise Ratio (SNR)","Measurement of signal-to-noise ratio for image quality assessment across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions.","Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.",{"measure":53,"description":54,"timeFrame":51},"Contrast-to-Noise Ratio (CNR)","Measurement of contrast-to-noise ratio for image quality assessment across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions.\n\nUnit of Measure: CNR (unitless, numeric ratio)",{"measure":56,"description":57,"timeFrame":51},"Coefficient of Variation (COV)","Measurement of the coefficient of variation in selected regions for evaluating image consistency across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions.\n\nUnit of Measure: Percentage (%)",{"measure":59,"description":60,"timeFrame":51},"Spatial Resolution (Full Width at Half Maximum - FWHM)","Assessment of spatial resolution using full width at half maximum (FWHM) across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions.\n\nUnit of Measure: Millimeters (mm)",{"measure":62,"description":63,"timeFrame":51},"Target-to-Background Ratio (TBR)","Assessment of target-to-background ratio for evaluating PSMA-expressing tissue contrast across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions.\n\nUnit of Measure: Ratio (unitless numeric ratio)",{"measure":65,"description":66,"timeFrame":51},"Qualitative Image Quality Score (Likert Scale)","Independent qualitative evaluation of overall image quality, lesion detectability, image noise, and artifacts by nuclear medicine physicians, assessed using a 5-point Likert scale.\n\nUnit of Measure: Score on Likert Scale (1-5; 1 = worst, 5 = best)",{"measure":68,"description":69,"timeFrame":51},"Inter-reader Agreement (Weighted Kappa Statistics)","Measurement of agreement among readers evaluating qualitative image quality scores, analyzed using weighted kappa statistics.\n\nUnit of Measure: Weighted kappa statistic (numeric value ranging from 0 to 1, 0 = no agreement, 1 = perfect agreement)",[],"ALL","18 Years","120 Years",{"inclusion":75,"exclusion":79,"raw_text":88},[76,77,78],"Age ≥18 years.","Ability to provide informed consent and comply with study procedures.","For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential.",[80,81,82,83,84,85,86,87],"Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total).","More than four prior enrollments in this study.","Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan","Medication \\& Prior Treatment Exclusions","Concurrent PSMA-targeted therapy (e.g., lutetium-177).","Pregnant or breastfeeding individuals (negative pregnancy test required)","Inability to provide informed consent","Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.","Inclusion Criteria:\n\n* Age ≥18 years.\n* Ability to provide informed consent and comply with study procedures.\n* For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential.\n\nExclusion Criteria:\n\n* Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total).\n* More than four prior enrollments in this study.\n* Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan\n* Medication \\& Prior Treatment Exclusions\n* Concurrent PSMA-targeted therapy (e.g., lutetium-177).\n* Pregnant or breastfeeding individuals (negative pregnancy test required)\n* Inability to provide informed consent\n* Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.",[90,91],"ADULT","OLDER_ADULT",[93],{"facility":94,"city":95,"state":96,"zip":97,"country":98,"geoPoint":99},"Nuclear Imaging Institute","Englewood","New Jersey","07631","United States",{"lat":100,"lon":101},40.89288,-73.97264,[],[],[],[],{"nct_id":4,"conditions":107,"biomarkers":110},[108,19,109,22],"Coronary Artery Disease","Ischemic Heart Disease",[],{"nct_id":4,"found":112,"summary":113,"prompt_version":113},false,null]